Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06601218 · ClinicalTrials.gov registry record · Phase 1
Impact of Daily Oral Cannabis Doses in Patients With Cancer
A Phase 1 study of Cancer and Cancers, Pain, sponsored by Shanna Babalonis, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06601218: Recruiting Phase 1 study of Cancer and Cancers, Pain, sponsored by Shanna Babalonis, PhD.
NCT06601218 is a Phase 1 study of Cancer and Cancers, Pain that is actively recruiting participants, run by Shanna Babalonis, PhD. The registered enrollment target is 80 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06601218, a Phase 1 study of Cancer and Cancers, Pain, is actively recruiting participants, sponsored by Shanna Babalonis, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will enroll patients with cancer and participants will be randomized to receive one dose of cannabis for approximately 4 months. There is a 3/4 (or 75%) chance that a participant will receive an active cannabis dose in the study. There is a 1/4 (or 25% chance) that a participant will receive a placebo dose (meaning a blank dose/no cannabis/no active drug). The goals of this study are to determine 1) the safety and tolerability of cannabis in individuals with cancer and 2) if cannabis can help with the side effects of cancer and cancer treatment - including nausea and vomiting, appetite, pain, sleep, and quality of life.
Primary Outcome
The percent of patients who elect to withdrawal from the study or removed by physician/investigators due AEs or safety concerns in each group will be measured and compared to the placebo group.
Conditions Studied
Interventions
- DRUG Oral cannabis low THC
- DRUG Placebo Comparator
- DRUG Oral cannabis high THC
- DRUG Oral cannabis THC/CBD
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 1 |
What NCT06601218 shows while recruiting
NCT06601218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which Oral cannabis low THC is the first listed.
NCT06601218 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06601218 about?
NCT06601218 is a clinical study titled "Impact of Daily Oral Cannabis Doses in Patients With Cancer". This study will enroll patients with cancer and participants will be randomized to receive one dose of cannabis for approximately 4 months. There is a 3/4 (or 75%) chance that a participant will receive an active cannabis dose in the study. There is a 1/4 (or 25% chance) that a participant will rece...
What is the current status of trial NCT06601218?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2025-06-17. Estimated completion is 2030-12-01.
What conditions does trial NCT06601218 study?
This clinical trial studies the following conditions: Cancer, Cancers, Pain.
What interventions are being tested in trial NCT06601218?
The interventions under investigation include: Oral cannabis low THC (DRUG), Placebo Comparator (DRUG), Oral cannabis high THC (DRUG), Oral cannabis THC/CBD (DRUG).
Who is sponsoring clinical trial NCT06601218?
This trial is sponsored by Shanna Babalonis, PhD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06601218 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06601218's enrollment target sits among peer trials
80 349th of 615 higher than 255 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI